Cxbladder Monitor is a non-invasive urine-based laboratory test designed to help rule out the recurrence of bladder cancer. It offers a new approach and potential alternative to the current invasive surveillance protocol for many patients.

Accurate

Cxbladder Monitor accurately helps to rule out recurrent urothelial carcinoma (UC), delivering a combined segregation score calculated from five genotypic biomarkers in the urine, and from clinical information about previous UC.1

Reliable

Cxbladder Monitor delivers a reliable and accurate test result to you and your patient. With high negative predictive value (97.0%) and sensitivity (93.0%), Cxbladder Monitor helps you to confidently rule out patients with a low risk of recurrent disease, and identify those who are at higher risk of recurrence and who may need further clinical workup.

Clinical applications

  • Replace other urine-based tests used in surveillance for recurrent UC
  • Used throughout surveillance for recurrent UC as the preferred adjunct to cystoscopy
  • Used as a confirmatory negative adjunct to cystoscopy, reducing the need for additional investigational tests and procedures in the future
  • Continue surveillance for recurrent UC patients
  • Monitor patients who may not tolerate cystoscopy for medical or religious reasons
  • Improve patient compliance with accurate and non-invasive testing

Other benefits

  • Only a small sample of urine is needed and refrigeration is not required
  • Our qualified laboratory will return the test results within seven working days from receipt of sample
  • References

    Kavalieris L, O’Sullivan PJ, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426. [pdf available]


    Lotan Y, Hershey JR, Shariat S, et al. The development and clinical validation of a high sensitivity urine biomarker test for the determination of recurrence in urothelial carcinoma patients. American Urological Association Annual Meeting 2016; San Diego, CA, USA. Read abstract


    Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017;:1–8. [pdf available]